EGFR tyrosine kinase inhibitor receipt and overall survival in metastatic non-small cell lung cancer in Egypt A retrospective descriptive cohort study
This retrospective cohort study of 99 Egyptian patients with EGFR-mutated metastatic non-small cell lung cancer found that while 73.7% received EGFR tyrosine kinase inhibitors, the resulting survival estimates are limited by heavy censoring and missing outcomes among untreated patients, preventing definitive conclusions on treatment effects or population-level access.